Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.

Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK.

J Clin Oncol. 2010 Mar 20;28(9):1502-7. doi: 10.1200/JCO.2009.24.7759. Epub 2010 Feb 16.

2.

Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.

La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.

Am J Clin Oncol. 2010 Jun;33(3):217-20. doi: 10.1097/COC.0b013e3181a650a6.

PMID:
19745694
3.

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.

Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H.

Eur Urol. 2008 Dec;54(6):1373-8. doi: 10.1016/j.eururo.2008.07.051. Epub 2008 Aug 8.

PMID:
18692304
4.

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.

Br J Dermatol. 2009 Nov;161(5):1045-51. doi: 10.1111/j.1365-2133.2009.09290.x. Epub 2009 May 5.

PMID:
19558553
5.

The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.

Cowey CL, Fielding JR, Rathmell WK.

Urology. 2010 May;75(5):1108-13.e1. doi: 10.1016/j.urology.2009.06.105. Epub 2009 Nov 20.

PMID:
19931124
6.

A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.

Richards TM, Plowman PN, Reznek R, Ball SA.

Clin Oncol (R Coll Radiol). 2009 Oct;21(8):633-4. doi: 10.1016/j.clon.2009.03.001. Epub 2009 Apr 19. No abstract available.

PMID:
19380217
7.

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V.

Eur Urol. 2010 Dec;58(6):906-11. doi: 10.1016/j.eururo.2010.09.008. Epub 2010 Sep 24.

PMID:
20884115
8.

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.

Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C.

Clin Cancer Res. 2007 Mar 15;13(6):1801-9.

9.

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ.

J Clin Oncol. 2007 Aug 1;25(22):3288-95.

PMID:
17664476
10.

Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.

Yuasa T, Urakami S, Yamamoto S, Yonese J, Nakano K, Kodaira M, Takahashi S, Hatake K, Inamura K, Ishikwa Y, Fukui I.

Urology. 2011 Apr;77(4):831-5. doi: 10.1016/j.urology.2010.12.008. Epub 2011 Feb 12.

PMID:
21316083
11.

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.

Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED; Southwest Oncology Group.

J Clin Oncol. 2007 Aug 1;25(22):3296-301.

PMID:
17664477
12.

Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.

Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Nishikawa T, Nakano M, Tanabe K.

Jpn J Clin Oncol. 2010 Dec;40(12):1173-9. doi: 10.1093/jjco/hyq150. Epub 2010 Aug 9.

PMID:
20696817
13.

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.

Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K, Escudier B.

Ann Oncol. 2011 Aug;22(8):1812-23. doi: 10.1093/annonc/mdq651. Epub 2011 Feb 15.

PMID:
21324953
14.

Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.

Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF.

BJU Int. 2012 Sep;110(5):692-8. doi: 10.1111/j.1464-410X.2012.10946.x. Epub 2012 Feb 24.

15.

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.

Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM.

J Urol. 2008 Jan;179(1):81-6; discussion 86. Epub 2007 Nov 12.

PMID:
17997441
16.

Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.

Staehler M, Haseke N, Roosen A, Stadler T, Bader M, Siebels M, Karl A, Stief CG.

Eur J Med Res. 2010;15:287-91.

17.

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.

Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, Signoretti S, Mier JW, Atkins MB, Bhatt RS.

J Transl Med. 2011 Dec 21;9:220. doi: 10.1186/1479-5876-9-220.

18.

Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.

Johannsen M, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V.

Eur Urol. 2009 Jun;55(6):1430-8. doi: 10.1016/j.eururo.2008.10.021. Epub 2008 Oct 18.

PMID:
18950936
19.
20.

Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.

Herrmann E, Marschner N, Grimm MO, Ohlmann CH, Hutzschenreuter U, Overkamp F, Groschek M, Blumenstengel K, Pühse G, Steiner T.

World J Urol. 2011 Jun;29(3):361-6. doi: 10.1007/s00345-011-0673-4. Epub 2011 Apr 3.

PMID:
21461939

Supplemental Content

Support Center